4/7
08:02 am
akba
Akebia Therapeutics (AKBA) had its "buy" rating reaffirmed by BTIG Research. They now have a $4.00 price target on the stock.
Low
Report
Akebia Therapeutics (AKBA) had its "buy" rating reaffirmed by BTIG Research. They now have a $4.00 price target on the stock.
4/7
08:00 am
akba
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
Low
Report
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
4/6
03:32 am
akba
How The Akebia Therapeutics (AKBA) Narrative Is Shifting After Vafseo Revenue And Protocol Updates [Yahoo! Finance]
Medium
Report
How The Akebia Therapeutics (AKBA) Narrative Is Shifting After Vafseo Revenue And Protocol Updates [Yahoo! Finance]
4/2
04:56 pm
akba
Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day Transcript [Seeking Alpha]
Medium
Report
Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day Transcript [Seeking Alpha]
4/2
04:05 pm
akba
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/2
12:20 pm
akba
Akebia Therapeutics R&D Day: Vafseo Growth Plan, Praliciguat Phase 2, New Kidney Pipeline Targets [Yahoo! Finance]
Low
Report
Akebia Therapeutics R&D Day: Vafseo Growth Plan, Praliciguat Phase 2, New Kidney Pipeline Targets [Yahoo! Finance]
4/1
04:05 pm
akba
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
Low
Report
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
3/31
03:45 am
akba
Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy [Yahoo! Finance]
Medium
Report
Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy [Yahoo! Finance]
3/19
04:55 pm
akba
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 [Yahoo! Finance]
Low
Report
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 [Yahoo! Finance]
3/19
04:05 pm
akba
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026
Neutral
Report
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026
3/10
07:06 am
akba
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/9
10:56 pm
akba
Akebia Therapeutics Details Vafseo Commercial Push, TIW Dosing Plans and Kidney Pipeline at Leerink Conference [Yahoo! Finance]
Low
Report
Akebia Therapeutics Details Vafseo Commercial Push, TIW Dosing Plans and Kidney Pipeline at Leerink Conference [Yahoo! Finance]
3/9
06:11 pm
akba
Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
Low
Report
Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
3/8
08:03 pm
akba
How The Akebia Therapeutics (AKBA) Story Is Shifting As Vafseo Revenue Assumptions Reset [Yahoo! Finance]
Medium
Report
How The Akebia Therapeutics (AKBA) Story Is Shifting As Vafseo Revenue Assumptions Reset [Yahoo! Finance]
3/3
08:00 am
akba
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
Low
Report
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
3/2
04:05 pm
akba
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/28
05:57 am
akba
Akebia Therapeutics (AKBA) was downgraded by Zacks Research from "hold" to "strong sell".
Medium
Report
Akebia Therapeutics (AKBA) was downgraded by Zacks Research from "hold" to "strong sell".
2/26
09:43 am
akba
Akebia Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Akebia Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/26
07:42 am
akba
Akebia Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
Low
Report
Akebia Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
2/26
07:32 am
akba
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights [Yahoo! Finance]
Low
Report
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights [Yahoo! Finance]
2/26
07:00 am
akba
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
Medium
Report
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
2/25
08:03 am
akba
Akebia Therapeutics (AKBA) had its price target lowered by BTIG Research from $5.00 to $4.00. They now have a "buy" rating on the stock.
Medium
Report
Akebia Therapeutics (AKBA) had its price target lowered by BTIG Research from $5.00 to $4.00. They now have a "buy" rating on the stock.
2/19
08:27 am
akba
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights [Yahoo! Finance]
Low
Report
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights [Yahoo! Finance]
2/19
08:00 am
akba
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights
Low
Report
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights
2/13
04:58 pm
akba
Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]
Low
Report
Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]